content_copy Immunotherapy of Solid Tumor Cancers: Role of Cancer Associated Fibrob - Vitro Biopharma

Immunotherapy of Solid Tumor Cancers: Role of Cancer Associated Fibroblasts

August 14, 2021

Immunotherapy of Solid Tumor Cancers: Role of Cancer Associated Fibroblasts

December 12, 2017

Cancer therapy traditionally involves surgery, radiation or chemotherapy to kill cancer cells that are normal cells lacking control that limit growth.  Cancer cells produce continually growing tumors that spread to other tissues, and eventually kill. Since the early 1990’s, other targeted therapies have been developed with fewer side-effects. During 2017, the first CAR-T immunotherapies were FDA approved for treatment of both leukemia and lymphoma.

CAR T-cell therapy involves genetic engineering of patient’s T cells (an immune cell that attacks foreign cells) so they attack and destroy cancer cells. T-cells are taken from patient’s blood, expanded, and the gene for the cancer’s antigen is expressed in the T-cells. The special antigen is called a chimeric antigen receptor (CAR). Large numbers of the CAR T-cells are grown in the laboratory and infused back into the patient[1].

CAR T-cells bind to antigens present on the cancer cell surface, and then selectively destroy just the cancer cells resulting in minimal side-effects.  This works very well with blood cancers such as leukemia and lymphoma.  However, CAR T-cell therapy has reduced effects on solid tumors found in breast, lung, pancreatic, and other solid tumors. This is because tumor antigens reside on the surface of cancer cells buried within the tumor, where they are surrounded and protected by cancer associated fibroblasts (CAFs) [2].

Cancer associated fibroblasts are a subpopulation of cells that reside within the tumor microenvironment that promote the transformation process by encouraging tumor growth, angiogenesis, inflammation, and metastasis[3]. These cells have been shown to provide a barrier to solid tumors by acting as a defensive shield, blocking the interaction of immune cells and CAR T-cells with cancerous cells.

Vitro Biopharma manufactures CAFs and media to support CAF expansion.  We offer CAFs from endometrial adenocarcinoma, colorectal, lung adenocarcinoma, lung squamous carcinoma, pancreatic, breast, melanoma, and ovarian tumors.  All CAFs are fully characterized by growth rates, maximum passage number, and expression of the biomarkers:  alpha-SMA, FAP, GFAP, FSP1, CD44, CD90, CD105, CD126, CD133, CD326 by flow cytometry and/or IHC.  We have sold these products to many different customers in academia and the biopharmaceutical industry for several years.  We offer extensive technical support of these products, opportunities for partnership/custom CAFs, multi-cell cultures and 2 or 3-D configuration.  Vitro Biopharma is a biopharmaceutical manufacturing entity with strict adherence to FDA-GMP guidelines.  For additional information see:  www.vitrobiopharma.com

By:  Tiana Tonrey, MS, Laboratory Manager, Vitro Biopharma, Richard Dean, Research Associate, Vitro Biopharma and Krutika Patell, Laboratory Technician, Vitro Biopharma

References:

  1. NCI Dictionary of Cancer Terms. NIH; [accessed at 2017 Dec 11]. https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=771302
  2. CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers. NIH; [updated 2017 Aug 31; accessed at 2017 Dec 11]. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
  3. Madar, S. Goldstein, I. Rotter V. Aug 2013. ‘Cancer associated fibroblasts’ – more than meets the eye. Trends in Molecular Medicine. [accessed at 2017 Dec 11];19(8):447-453.



Also in Blogs

Stem Cell Therapy of Stroke: Current Research Support and Clinical Studies
Stem Cell Therapy of Stroke: Current Research Support and Clinical Studies

August 14, 2021 0 Comments

Adult stem cell therapy is a common FDA-approved procedure for the treatment of blood disorders including leukemia, lymphoma and autoimmune diseases. Cell therapy using other types of adult stem cells including mesenchymal stem cells (MSCs), neural stem cells (NSCs) and muscle stem cells (Satellite cells).

Read More

Anti-Aging Stem Cell Therapy Improves Quality of Life
Anti-Aging Stem Cell Therapy Improves Quality of Life

August 14, 2021 0 Comments

Scientists at the University of Miami Miller School of Medicine completed a clinical trial showing safety and efficacy of stem cell therapy in treatment of frailty, a common aging symptom caused by reduced function of stem cells and inflammation.

Read More

Recent Advances in Stem Cell Therapy of Stroke
Recent Advances in Stem Cell Therapy of Stroke

August 14, 2021 0 Comments

An interim report of a clinical trial of intracerebral injection of stem cells adds to a growing body of evidence supporting safety and efficacy of stem cell therapy for stroke.  A clinical team led by Dr. Gary Steinberg at Stanford University Medical Center reported results from 16 patients who received stereotactic injections into damaged brain regions consisting of MSCs that were modified to facilitate their differentiation into neural stem cells.

Read More